Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2007 May 21;96(10):1504-13.
doi: 10.1038/sj.bjc.6603756. Epub 2007 Apr 24.

Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients

E de Azambuja  1 , F Cardoso, G de Castro Jr, M Colozza, M S Mano, V Durbecq, C Sotiriou, D Larsimont, M J Piccart-Gebhart, M Paesmans
Affiliations
Meta-Analysis

Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients

E de Azambuja et al. Br J Cancer. .

Abstract

The Ki-67 antigen is used to evaluate the proliferative activity of breast cancer (BC); however, Ki-67's role as a prognostic marker in BC is still undefined. In order to better define the prognostic value of Ki-67/MIB-1, we performed a meta-analysis of studies that evaluated the impact of Ki-67/MIB-1 on disease-free survival (DFS) and/or on overall survival (OS) in early BC. Sixty-eight studies were identified and 46 studies including 12 155 patients were evaluable for our meta-analysis; 38 studies were evaluable for the aggregation of results for DFS, and 35 studies for OS. Patients were considered to present positive tumours for the expression of Ki-67/MIB-1 according to the cut-off points defined by the authors. Ki-67/MIB-1 positivity is associated with higher probability of relapse in all patients (HR=1.93 (95% confidence interval (CI): 1.74-2.14); P<0.001), in node-negative patients (HR=2.31 (95% CI: 1.83-2.92); P<0.001) and in node-positive patients (HR=1.59 (95% CI: 1.35-1.87); P<0.001). Furthermore, Ki-67/MIB-1 positivity is associated with worse survival in all patients (HR=1.95 (95% CI: 1.70-2.24; P<0.001)), node-negative patients (HR=2.54 (95% CI: 1.65-3.91); P<0.001) and node-positive patients (HR=2.33 (95% CI: 1.83-2.95); P<0.001). Our meta-analysis suggests that Ki-67/MIB-1 positivity confers a higher risk of relapse and a worse survival in patients with early BC.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Results of the meta-analysis with all evaluable studies for DFS. A hazard ratio (HR)>1 implies a worse DFS for the group with increased Ki-67. The squared size is proportional to the number of patients included in each study. The centre of the lozenge gives the combined HR for the meta-analysis and its extremities the 95% CI.
Figure 2
Figure 2
Results of the meta-analysis with all evaluable studies for OS. A HR>1 implies a worse OS for the group with increased Ki-67. The squared size is proportional to the number of patients included in each study. The centre of the lozenge gives the combined HR for the meta-analysis and its extremities the 95% CI.
See this image and copyright information in PMC

References

    1. Alonzo TA (2005) Standards for reporting prognostic tumor marker studies. J Clin Oncol 23: 9053–9054 - PubMed
    1. Beck T, Weller EE, Weikel W, Brumm C, Wilkens C, Knapstein PG (1995) Usefulness of immunohistochemical staining for p53 in the prognosis of breast carcinomas: correlations with established prognosis parameters and with the proliferation marker, MIB-1. Gynecol Oncol 57: 96–104 - PubMed
    1. Bevilacqua P, Verderio P, Barbareschi M, Bonoldi E, Boracchi P, Dalla Palma P, Gasparini G (1996) Lack of prognostic significance of the monoclonal antibody Ki-S1, a novel marker of proliferative activity, in node-negative breast carcinoma. Breast Cancer Res Treat 37: 123–133 - PubMed
    1. Biesterfeld S, Kluppel D, Koch R, Schneider S, Steinhagen G, Mihalcea AM, Schroder W (1998) Rapid and prognostically valid quantification of immunohistochemical reactions by immunohistometry of the most positive tumour focus. A prospective follow-up study on breast cancer using antibodies against MIB-1, PCNA, ER, and PR. J Pathol 185: 25–31 - PubMed
    1. Billgren AM, Tani E, Liedberg A, Skoog L, Rutqvist LE (2002) Prognostic significance of tumor cell proliferation analyzed in fine needle aspirates from primary breast cancer. Breast Cancer Res Treat 71: 161–170 - PubMed

Publication types